EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin

Rıdvan Bora iD, Burak Toprak iD, Emrah Yeşil iD, Rojda Tanrıverdi, Muhammed Adıyaman iD, Mustafa Demir iD, Oben Döven

Journal of Clinical Medicine · 06.06.2026 · 15 (12) · 4400

DOI: 10.3390/jcm15124400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.06.2026. Verfasst von Rıdvan Bora und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Mersin City Education and Research Hospital, 33240 Mersin, Turkey. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mersin University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammation plays a central role in the pathophysiology of acute coronary syndrome (ACS). Raftlin, a lipid raft-associated inflammatory protein involved in immune signaling, has emerged as a potential biomarker in cardiovascular disease. This study aimed to evaluate circulating raftlin levels and RFTN1 rs690037 polymorphism in patients with ACS.

Methods

This prospective observational study included 100 participants comprising 50 patients diagnosed with ACS and 50 control subjects with angiographically normal coronary arteries. Serum raftlin concentrations were measured using enzyme-linked immunosorbent assay, and RFTN1 rs690037 polymorphisms were analyzed by real-time polymerase chain reaction. Correlation, receiver operating characteristic (ROC), multivariable logistic regression, and net reclassification improvement (NRI) analyses were performed.

Results

Serum raftlin levels were significantly higher in the ACS group compared with controls (4.28 [3.48–5.78] vs. 3.38 [2.66–4.23] ng/dL, p = 0.003). Raftlin levels demonstrated significant positive correlations with LDL cholesterol and HbA1c levels in ACS patients (p < 0.05 for both). ROC analysis showed that raftlin had moderate discriminative ability for ACS detection (AUC: 0.672, 95% CI: 0.570–0.762, p = 0.002). Although raftlin was not independently associated with ACS after multivariable adjustment, incorporation of raftlin into the baseline clinical model improved overall risk classification (NRI: 0.213, p = 0.041). No significant association was observed between RFTN1 rs690037 polymorphism and ACS or circulating raftlin levels.

Conclusions

Circulating raftlin levels are elevated in patients with ACS and appear to reflect the inflammatory and metabolic dysregulation accompanying acute coronary events. Although raftlin alone demonstrated limited diagnostic performance, its incremental contribution to multimarker risk assessment models suggests potential utility as a complementary inflammatory biomarker in ACS. Larger multicenter studies are warranted to clarify its prognostic and translational significance.

Schlagwörter

Stichwörter der Autor:innen

acute coronary syndromeatherosclerosisgene polymorphisminflammationraftlin

Autor:innen und Institutionen

  • Department of Cardiology, Mersin City Education and Research Hospital, 33240 Mersin, Turkey.
  • Department of Cardiovascular Surgery, Mersin City Education and Research Hospital, 33120 Mersin, Turkey.
  • Department of Cardiology, Mersin University Faculty of Medicine Hospital, 33343 Mersin, Turkey.
  • Department of Biochemistry, Mersin University Faculty of Medicine Hospital, 33110 Mersin, Turkey.
  • Department of Cardiology, Private Genesis Hospital, 21070 Diyarbakır, Turkey.
  • Department of Cardiology, Defne State Hospital, 31160 Hatay, Turkey.

ORCID-Profile: Rıdvan Bora, Burak Toprak, Emrah Yeşil, Muhammed Adıyaman, Mustafa Demir

Förderung

  • Mersin University

Zitieren

APA

Bora, R., Toprak, B., Yeşil, E., Tanrıverdi, R., Adıyaman, M., Demir, M., & Döven, O. (2026). A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin. Journal of Clinical Medicine, 15(12), 4400. https://doi.org/10.3390/jcm15124400

Vancouver

Bora R, Toprak B, Yeşil E, Tanrıverdi R, Adıyaman M, Demir M, et al. A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin. Journal of Clinical Medicine. 2026;15(12):4400. doi:10.3390/jcm15124400

BibTeX
@article{Bora2026,
  author = {Bora, Rıdvan and Toprak, Burak and Yeşil, Emrah and Tanrıverdi, Rojda and Adıyaman, Muhammed and Demir, Mustafa and Döven, Oben},
  title = {A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4400},
  doi = {10.3390/jcm15124400}
}
Kostenlos starten →